USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Cyfuse Biomedical K.k.

USPTO PatentsView assignee record - 8 granted patents across 7 technology areas, active 2016–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12M (APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERME).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

Total patents granted

CPC technology areas

9.9

Avg claims per patent

+67%

5-year filing velocity

The verdict

Cyfuse holds 8 US patents across 7 technology areas, rank #31,239 of 50,000 tracked assignees.

#31,239
of 50,000 US assignees by volume: Top 69%
by Innovation Score (29.5/100): 9.9
avg claims per patent: +67%
filing velocity, last 5 yrs

Portfolio overview

Cyfuse Biomedical K.k. has been granted 8 US utility patents between 2016 and 2025, placing Cyfuse Biomedical K.k. at rank #31,239 across all assignees tracked by PlainPatent. This portfolio spans 7 distinct Cooperative Patent Classification (CPC) subclasses, averaging 9.9 claims per patent with primary concentration in C12M (APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERME). As a Foreign Corporation, Cyfuse Biomedical K.k. is one of the more focused assignees in the PatentsView dataset. By volume, Cyfuse sits between Cutting EDGE Spine Llc (8 patents, rank #31,235) and Calibre International, Llc (8 patents, rank #31,243) - the closest US assignees by grant volume. The composite Innovation Score of 29.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 5 grants, compared with 3 in the 2015–2019 window, a +67% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Cyfuse Biomedical K.k.'s 9.9 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 7 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Cyfuse Biomedical K.k. against peers pursuing similar technology classes.

Cutting EDGE Spine

8
CY Cergy Paris Un…

8
CY Vision

8
Cybertoka

8
Cake 0 emission AB

8
Calabazas Creek R…

8
Caliber

8
Calibre Internati…

8
Cyfuse Biomedical… ◀

8

What this shows Cyfuse holds 8 patents at rank #31,239, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Cyfuse

By rank, the assignees closest to #31,239 in granted patent volume.

Leaders in C12M (Apparatus FOR Enzymology OR Microbiology)

Other assignees with the most granted patents in Cyfuse's primary technology class.

Cyfuse's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

30 Top 69% higher than 31% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Cyfuse Biomedical K.k. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	2	25.0%
2018	1	12.5%
2021	1	12.5%
2024	1	12.5%
2025	3	37.5%

Which technologies does Cyfuse Biomedical K.k. patent most?

C12M - APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS 7

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 4

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 2

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 2

G06V - IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING 1

B33Y - ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING 1

A61B - DIAGNOSIS; SURGERY; IDENTIFICATION 1

Top 7 of 7 technology areas

Patent Moat Analysis

Portfolio Volume Light

Tech Breadth Focused

Claim Depth Simple

Velocity Accelerating

Where it ranks

Overall rank by patents

#31,239

Across all tracked assignees

Innovation Score

29.5 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Cyfuse Biomedical K.k. hold?

Cyfuse Biomedical K.k. holds 8 US granted patents filed between 2016 and 2025, spanning 7 technology areas.

What is Cyfuse Biomedical K.k.'s Innovation Score?

Cyfuse Biomedical K.k. has an Innovation Score of 29.5 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Cyfuse Biomedical K.k. focus on?

Cyfuse Biomedical K.k.'s top technology area is C12M (APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS) with 7 patents. The company has filed patents in 7 CPC subclasses total.

Is Cyfuse Biomedical K.k.'s patent filing rate increasing or decreasing?

Cyfuse Biomedical K.k.'s recent filing velocity is +67% compared to the prior five-year period. This indicates accelerating innovation.

What does claim depth mean for Cyfuse Biomedical K.k.'s patents?

Cyfuse Biomedical K.k.'s patents average 9.9 claims each. This is relatively simple claim structure, typical for focused inventions.

How is the Cyfuse Biomedical K.k. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Cyfuse's 8 grants land it in the top 69% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Cyfuse ranks #31,239 of 50,000. Top 50 holders
Most of this portfolio concentrates in C12M - see who else leads that technology area. C12M leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.